Short answer
Arbutus Biopharma Corp (ABUS) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $179M (up 10054.5% year over year) with net income of $170M.
Q1 2026 key financials · XBRL
- Revenue
- $179M
- +10054.5% YoY
- Net income
- $170M
- +791.9% YoY
- Operating margin
- 94.3%
- EPS (diluted)
- $0.87
- +769.2% YoY
Source: XBRL data from the Arbutus Biopharma Corp (ABUS) Q1 2026 10-Q on SEC EDGAR. USD.
Arbutus Biopharma Corp Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue and YoY change not provided in supplied MD&A
- Profitability or margin percentages not provided in supplied MD&A
- Best-performing line: IM-PROVE II nivolumab cohort, 25% functional cure rate
- Moderna settlement: $950.0M noncontingent payment, estimated $178.7M Arbutus share
- Potential third-quarter 2026 shareholder capital return following settlement receipt; imdusiran received FDA Fast Track designation
Risk Factors
- No material changes from risk factors disclosed in the December 31, 2025 Form 10-K
- No newly added risk factor identified for the quarter ended March 31, 2026
- Settlement Agreement dated March 3, 2026, with Moderna and Genevant, included by reference without disclosed risk-factor changes
- No new unregistered equity sales or senior-security defaults during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arbutus Biopharma Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.